Edap Tms earnings release, August 13, 2026

Edap Tms Sa (FOCL) · Form 8-K, Item 2.02 · Filed · SEC filing

FocalTherics™

Reports Second Quarter 2026 Financial Results

39%

Revenue Increase and 47% Growth in U.S. Procedures

AUSTIN,

Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.

Second

Quarter 2026 Results and Recent Highlights of Continuing Operations (HIFU Segment)

“We continue to demonstrate commercial success with our strongest second quarter ever, reflecting the growing strength of our core business and further supporting the strategic shift to Focal Therapy with our corporate rebranding to FocalTherics,” said Ryan Rhodes, CEO of FocalTherics. “Along with strong commercial momentum, we are also pleased with the developing progress of the endometriosis commercial launch in Europe and look forward to establishing additional Focal One programs to increase access to an important, non-surgical option for women with this highly debilitating condition. In addition, with expected proceeds from our ongoing capital raise, we will continue to accelerate commercial adoption in the global prostate cancer market while leveraging our multi-indication Focal One platform to grow market opportunities in treating endometriosis and expanding into benign prostatic hyperplasia or BPH. We will also continue to invest in our innovation and product development initiatives driving advances in AI-assisted treatments, FocalConnect™ telecollaboration technology, and integrating histotripsy together with HIFU on our Focal One platform.”

Second

Quarter 2026 Financial Results for Continuing Operations (HIFU Segment)

Total revenue for the second quarter of 2026 was $13.2 million, compared to $9.5 million for the same period in 2025, representing an increase of 39% year-over-year. The Company sold thirteen Focal One systems during the quarter, versus nine systems in the same period in 2025, representing a year-over-year growth of 44%. The Company’s U.S. Focal One procedures grew 47% year-over-year.

Gross margin for the second quarter of 2026 was 55.6%, compared to 51.1% in the prior year period. The increase in gross margin was primarily attributable to improvement of the standard cost of the Focal One system and favorable absorption due to higher production volumes.

Operating expenses were $15.4 million for the second quarter of 2026, compared to $11.5 million in the prior year period. These expenses included approximately $0.8 million in one-time costs primarily attributable to corporate initiatives regarding rebranding, domestic filer transition and discontinued operations classification.

Operating loss was $8.0 million for the second quarter of 2026, compared to $6.6 million in the prior year period. Net loss was $14.4 million for the second quarter of 2026, or ($0.38) per share, compared to a net loss of $6.4 million, or ($0.17) per share in the prior year period.

The increase in net loss was primarily attributable to the European Investment Bank warrant valuation impact of $5.5 million during the quarter.

Cash and cash equivalents as of June 30, 2026 totaled $21.5 million.

Reiterating

2026 Guidance for Continuing Operations (HIFU Segment)

Discontinued

Operations

During the second quarter of 2026, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company’s operations and financial results.

Accordingly, the Company’s unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company’s

ESWL and Distribution operating segments as discontinued operations.

Prior-period results presented in this release have been recast to reflect this classification on a consistent basis. As a result, all continuing operations figures and growth rates presented herein reflect the Company's HIFU business only.

Conference

Call Information

A conference call and webcast to discuss the second quarter 2026 financial results will be hosted by Ryan Rhodes, Chief Executive Officer and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.

About

FocalTherics

A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform,

Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended: — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands of U.S. Dollars, except per share data)

Three Months Ended: – June 30, – 2026 – $USThree Months Ended: – June 30, – 2025 – $US
Sales of goods9,5276,385
Sales of RPPs & leases2,7582,155
Sales of spare parts and services918969
TOTAL NET SALES13,2039,509
Other revenues0
TOTAL REVENUES13,2039,509
Cost of sales-5,865-4,646
GROSS PROFIT7,3384,863
Research & development expenses-2,317-2,291
Selling, general & administrative expenses-13,054-9,194
Total operating expenses-15,371-11,485
LOSS FROM OPERATIONS-8,033-6,623
Interest (expense) income, net-748-79
Loss from change in fair value of warrant liability-5,547
Currency exchange gains (loss), net-76362
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS-14,404-6,340
Income tax (expense) credit, net from continuing operations-8-14
LOSS FROM CONTINUING OPERATIONS-14,412-6,354
Income(loss) from discontinued operations, net of tax-75-51
NET LOSS-14,487-6,406
Loss per share – Basic and diluted-0.39-0.17
Average number of shares used in computation of EPS - basic and dilutive37,527,95037,420,318

Income Statement

Six Months Ended: — (Amounts in thousands of U.S. Dollars, except per share data)

Six Months Ended: – June 30, – 2026 – $USSix Months Ended: – June 30, – 2025 – $US
Sales of goods17,78210,185
Sales of RPPs & leases5,2504,100
Sales of spare parts and services1,7641,724
TOTAL REVENUES24,79616,009
Cost of sales-11,496-7,989
GROSS PROFIT13,3008,020
Research & development expenses-4,784-4,648
Selling, general & administrative expenses-24,574-16,739
Total operating expenses-29,357-21,388
LOSS FROM OPERATIONS-16,057-13,368
Interest (expense) income, net-1,151-81
Loss from change in fair value of warrant liability-6,851
Currency exchange gains (loss), net77-664
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS-23,982-14,113
Income tax (expense) credit, net from continuing operations-25-23
LOSS FROM CONTINUING OPERATIONS-24,007-14,135
Income(loss) from discontinued operations, net of tax437285
NET LOSS-23,570-13,850
Loss per share – Basic and diluted-0.63-0.37
Average number of shares used in computation of EPS - basic and dilutive37,481,98637,406,202

Income Statement

Six months ended — (Amounts in thousands of U.S. Dollars)

June 30, 2026 – HIFU – DivisionJune 30, 2026 – Reconciling – ItemsJune 30, 2026 – Total After – Consolidation
Sales of goods17,78217,782
Sales of RPPs & leases5,2505,250
Sales of spare parts and services1,7641,764
TOTAL REVENUES24,79624,796
GROSS PROFIT (% of Net Sales)13,30013,300
Research & development expenses-4,784-4,784
Selling, general & administrative expenses-20,309-4,265-24,574
OPERATING PROFIT (LOSS)-11,792-4,265-16,057

Balance Sheet

December 31, — (Amounts in thousands of U.S. Dollars)

June 30, – 2026 – $USDecember 31, – 2025 – $US
Cash, cash equivalents21,54220,452
Accounts receivable, net10,06014,948
Inventory8,2517,770
Other current assets2,3502,439
Total current assets of discontinued operations16,81211,555
TOTAL CURRENT ASSETS59,01557,164
Property, plant and equipment, net8,6358,789
Goodwill735757
Other non-current assets6,1646,181
Total non-current assets of discontinued operations6,106
TOTAL ASSETS74,54878,997
Accounts payable & other accrued liabilities17,83017,436
Deferred revenues, current portion6,3956,452
Short term borrowing1,8604,386
Other current liabilities1,7863,005
Total current liabilities of discontinued operations8,9785,862
TOTAL CURRENT LIABILITIES36,84937,141
Obligations under operating and finance leases non-current8351,183
Long-term debt, non-current37,19715,903
Deferred revenues, non-current923768
Other long-term liabilities1,9701,632
Total non-current liabilities of discontinued operations2,957
TOTAL LIABILITIES77,77359,584
TOTAL SHAREHOLDERS’EQUITY-3,22519,413
TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY74,54878,997

Cash Flow

Six Months Ended — (Amounts in thousands of U.S. Dollars)

Six Months Ended – June 30, – 2026 – ($US)Six Months Ended – June 30, – 2025 – ($US)
NET INCOME (LOSS)-23,570-13,850
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1)11,7503,024
OPERATING CASH FLOW-11,820-10,827
Increase/Decrease in operating assets and liabilities5,157779
NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES-6,663-10,047
Additions to capitalized assets produced by the company and other capital expenditures-2,017-2,917
NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES-2,017-2,917
NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES10,402-1,198
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS-6322,231
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS1,090-11,931
Full release

In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities

Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,”

“plan,” “intend,” “is designed to,” “may,” “might,” “potential,”

“objective,” “target,” “project,” “predict,” “forecast,” “ambition,”

“guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements... (truncated)ding matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved, and include statements such as quote from our Chief Executive Officer, the expected closing and proceeds from our offering, and our financial performance guidance. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the

Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk

Factors" in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

Investor

Contact

Louisa

Smith

Gilmartin

Group investor.relations@focalone.com

EDAP

TMS S.A.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.